22 BOSTON WHARF ROAD, BOSTON, MA
Announces ADS Ratio Change
Shareholder Approval at Special General Meeting on March 2, 2026
Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market
Shareholder Vote Results from Akari Therapeutics Special Meeting
Investor Presentation
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Interim CFO Appointment - Kameel Farag Named Chief Financial Officer
Akari Therapeutics Enters Into Securities Purchase Agreement for ADSs
FY 2025
Q3
Q2
Q1
FY 2024
Notice of Late Filing for Annual Report
Notice of Late Filing for Quarterly Report
Effectiveness Notice
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Notice of Exempt Offering of Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Amended Registration Statement for Depositary Shares
Submission Upload
Correspondence